Alcon Inc (ALC) Stock Price, Fundamentals & Analysis

What ALC does

Alcon Inc (ALC) researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care, offering equipment, instrumentation, diagnostics, intraocular lenses (IOLs), and other implantables, as well as consumables such as viscoelastics, surgical solutions, and incisional instruments. Its cataract portfolio includes the Unity CS, LenSx laser system, Verion reference unit and digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements, alongside the ADI cloud-based platform. Implantable products range from monofocal, Toric, and Presbyopia-Correcting IOLs to delivery systems such as AutonoMe and UltraSert. Alcon Inc (ALC) is listed on the SIX Swiss Exchange, where it is one of the healthcare names tracked alongside peers such as Lonza Group AG (LONN), Novartis International AG (NOVN), and Roche Holding AG (ROP).

Key numbers explained

• 53.3 CHF is the latest price per share on the SIX Swiss Exchange, the amount a buyer pays for one unit of ownership.
• The trailing P/E ratio of 49.4 compares the current price to the last twelve months of earnings, showing how much investors pay per dollar of recent profit.
• The forward P/E ratio of 14.7 uses expected future earnings, offering a sense of valuation relative to what analysts anticipate.
• Dividend yield of 0.53% indicates the annual dividend as a percentage of the share price, a measure of cash income returned to shareholders.
• Ex-dividend date of May 5, 2026 is the cutoff date; buyers on or after this date do not receive the next dividend payment.
• 27% of earnings paid out as dividends shows the portion of profit the company returns to shareholders rather than retaining for growth or balance sheet strength.
• Beta of 0.7 suggests the stock has historically moved less than the broader market, with a one-percent market move associated with roughly a 0.7% move in the share price.
• Market cap of 25.77B CHF reflects the total market value of all outstanding shares, used to classify company size.

What to watch

• Revenue growth of 8.7% year over year and 10.86B USD in trailing twelve-month revenue show the scale and recent top-line trajectory of the business.
• ProfitMargin of 5.9% and operatingMargin of 14.6% illustrate how much of each revenue dollar remains after costs and operating expenses.
• ReturnOnEquity of 2.9% measures how effectively the company generates profit from shareholders' equity.
• Debt-to-equity ratio of 24.5% indicates the relative weight of debt compared to equity in the capital structure.
• PriceToBook of 1.44 compares the market price to the book value of equity per share.
• NextEarningsDate of Nov 10, 2026 is the scheduled date for the company's next public earnings release.
• Lowest and highest price in the last 52 weeks of 47.8 – 68.34 CHF and a price change over the last 52 weeks of -9.7% frame the recent trading range and one-year performance.
• As a healthcare stock in the medical instruments and supplies sector, Alcon Inc (ALC) can be influenced by regulatory approvals, reimbursement policy changes, innovation cycles in cataract and vision care, and broader health-system spending trends. Investors also monitor its position relative to peers such as Farmaceutica Remedia SA (RMAH), Regis Healthcare (REG), Philips (PHIA), and Jiangsu Hengrui Medicine (600276).